SWANBIO THERAPEUTICS

Dead / Abandoned — Abandoned — no statement of use filed (as of 30 Sept 2024)

What this means for you

This application is over — abandoned 30 Sept 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
97187198
Mark type
Stylized text
Filed
23 Dec 2021
Published for opposition
02 Jan 2024
Abandoned
30 Sept 2024
Attorney of record
Christina M. Licursi

Goods and services

  • Class 005 — Pharmaceuticals: Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders; none of the foregoing constituting reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays
  • Class 042 — Scientific and technological services: Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development; none of the foregoing relating to reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays

Owner

Prosecution history

  • 30 Sept 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 30 Sept 2024 — ABANDONMENT - NO USE STATEMENT FILED
  • 27 Feb 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 02 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 02 Jan 2024 — PUBLISHED FOR OPPOSITION
  • 13 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 28 Nov 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 08 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 08 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 08 Sept 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 08 Jun 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 08 Jun 2023 — NON-FINAL ACTION E-MAILED
  • 08 Jun 2023 — NON-FINAL ACTION WRITTEN
  • 11 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 10 Apr 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE

View this trademark record on Marksy